Moberg Pharma AB (publ) (STO:MOB)
Sweden · Delayed Price · Currency is SEK | Market Cap | 509.55M +37.2% |
| Revenue (ttm) | 16.76M +35.8% |
| Net Income | -21.62M |
| EPS | -0.46 |
| Shares Out | 47.18M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 196,677 |
| Open | 10.52 |
| Previous Close | 11.00 |
| Day's Range | 10.20 - 10.96 |
| 52-Week Range | 7.53 - 14.12 |
| Beta | 1.11 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 12, 2026 |
About Moberg Pharma AB
Moberg Pharma AB (publ), a pharmaceutical company, develops and commercializes medical products primarily in Sweden. It offers MOB-015 for the treatment of nail fungus under the Terclara brand. The company was formerly known as Moberg Derma AB (publ) and changed its name to Moberg Pharma AB (publ) in May 2013. It has license agreement with Karo Healthcare for distribution in European market. Moberg Pharma AB (publ) was incorporated in 2006 and is based in Bromma, Sweden. [Read more]
Full Company ProfileFinancial Performance
In 2025, Moberg Pharma AB's revenue was 13.54 million, an increase of 37.99% compared to the previous year's 9.81 million. Losses were -27.24 million, -89.32% less than in 2024.
Financial StatementsNews
Moberg Pharma granted U.S. patent relating to improved dosing of MOB-015
STOCKHOLM, Nov. 3, 2026 /PRNewswire/ -- Moberg Pharma AB (OMX: MOB) today announced that the United States Patent and Trademark Office (USPTO) has granted a patent relating to an improved dosing regim...
Moberg's MOB-015 Shows Fungal Cure Across A Broad Range Of Terbinafine Susceptibility
(RTTNews) - Moberg Pharma AB (MOB.ST) announced the publication of new analyses in the Journal of Fungi, 2026 showing that Terbinafine maintained strong antifungal activity against dermatophytes, the ...
Moberg Pharma AB Quarterly report: Q2 2026
Moberg Pharma AB has published its Q2 2026 quarterly earnings report on August 13, 2026.
Moberg Pharma AB Slides: Q2 2026
Moberg Pharma AB has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 13, 2026.
Moberg Pharma AB Quarterly report: Q1 2026
Moberg Pharma AB has published its Q1 2026 quarterly earnings report on May 12, 2026.
Moberg Pharma AB Slides: FY 2026
Moberg Pharma AB has posted slides in relation to its FY 2026 quarterly earnings report, which was published on March 10, 2026.
Moberg Pharma AB Quarterly report: Q4 2025
Moberg Pharma AB has published its Q4 2025 quarterly earnings report on February 17, 2026.
Moberg Pharma AB Annual report: Q4 2025
Moberg Pharma AB has published its Q4 2025 annual report on February 17, 2026.
Moberg Pharma AB Slides: Investor presentation
Moberg Pharma AB has posted slides in relation to its latest quarterly earnings report, which was published on February 17, 2026.
Moberg Pharma AB Slides: Investor presentation
Moberg Pharma AB has posted slides in relation to its latest quarterly earnings report, which was published on December 9, 2025.
Moberg Pharma AB Quarterly report: Q3 2025
Moberg Pharma AB has published its Q3 2025 quarterly earnings report on November 11, 2025.
Moberg Pharma and Karo Healthcare enter into an exclusive license agreement for MOB-015/Terclara in Europe, expanding access and growth potential
STOCKHOLM , Nov. 5, 2025 /PRNewswire/ -- Moberg Pharma AB (publ) has entered into an exclusive licensing agreement with Karo Healthcare AB regarding the commercialization of MOB-015 (Terclara®) in Eur...
Moberg Pharma AB Quarterly report: Q2 2025
Moberg Pharma AB has published its Q2 2025 quarterly earnings report on August 12, 2025.
Moberg Pharma AB Slides: Q2 2025
Moberg Pharma AB has posted slides in relation to its Q2 2025 quarterly earnings report, which was published on August 12, 2025.
Moberg Pharma AB Quarterly report: Q1 2025
Moberg Pharma AB has published its Q1 2025 quarterly earnings report on May 13, 2025.
Moberg Pharma AB Slides: Q1 2025
Moberg Pharma AB has posted slides in relation to its Q1 2025 quarterly earnings report, which was published on May 13, 2025.
Moberg Pharma AB Earnings Call Transcript: Q4 2024
Terclara solidified market leadership in Sweden and began expansion into Norway, with further EU rollouts planned for 2026. U.S. launch is delayed pending new clinical data, but the company remains well-financed and focused on European growth.
Moberg Pharma AB Annual report: Q4 2024
Moberg Pharma AB has published its Q4 2024 annual report on February 11, 2025.
Moberg Pharma AB Slides: Q4 2024
Moberg Pharma AB has posted slides in relation to its Q4 2024 quarterly earnings report, which was published on February 11, 2025.
Moberg Pharma AB Quarterly report: Q4 2024
Moberg Pharma AB has published its Q4 2024 quarterly earnings report on February 11, 2025.
Moberg Pharma AB Transcript: Study Update
The North American phase III study for MOB-015 did not meet its primary endpoint, with only 1.5% complete cure and lower mycological cure rates than previous studies. Strategic focus is shifting to Europe, where Terclara leads the market and regulatory approvals are in place. European rollout is prioritized for 2026, with ongoing partner discussions.
Moberg Pharma AB Press release: Study Update
Moberg Pharma AB issued a press release on December 11, 2024, disclosing material business information to investors.
Moberg Pharma reports topline data in the North American phase 3 study and will regain rights to MOB-015 in EU
STOCKHOLM , Dec. 10, 2024 /PRNewswire/ -- Moberg Pharma AB (OMX: MOB) announces that MOB-015 (topical terbinafine) did not meet the primary endpoint in the phase 3 study using 8 weeks of daily dosing ...
Moberg Pharma AB Earnings Call Transcript: Q3 2024
Terclara led the Swedish market in Q3, achieving 34% value and 78% unit share, and drove 41% category growth. U.S. phase III results may fall short of expectations, but European expansion remains on track with approvals in 13 countries.
Moberg Pharma AB Slides: Q3 2024
Moberg Pharma AB has posted slides in relation to its Q3 2024 quarterly earnings report, which was published on November 12, 2024.